Contraception, Gender
Conditions
Keywords
progestin, testosterone, gender-affirming, bleeding
Brief summary
Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.
Interventions
BEHAVIORALBleeding data
Participants will report their daily bleeding patterns
Sponsors
University of California, San Diego
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* English-speaking currently have a uterus and ovaries * desire to initiate GATT * potential desire to initiate a progestin (within 14 days of GATT initiation)
Exclusion criteria
* previous gender-affirming surgery to remove their uterus and/or ovaries
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean days bleeding or spotting | Start of GATT to 30 days | mean number of days of bleeding or spotting during the 30 days after GATT initiation |
Countries
United States
Outcome results
None listed